Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 8/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GPR183 | P32249 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14387112 | 1.00 | CCR2 (0.56) | CCR2TDP1KDM4EALDH1A1KMT2A | |
| SCHEMBL5325885 | 0.87 | CCR2 (0.56) | CCR2GPR183 | |
| SCHEMBL14387117 | 0.87 | CCR2 (0.56) | CCR2GPR183 | |
| SCHEMBL5351851 | 0.87 | CCR2 (0.56) | CCR2TDP1GPR183 | |
| SCHEMBL14387113 | 0.87 | CCR2 (0.56) | CCR2TDP1GPR183 | |
| SCHEMBL5321988 | 0.86 | CCR2 (0.47) | CCR2GPR183 | |
| SCHEMBL14386903 | 0.86 | CCR2 (0.47) | CCR2GPR183 | |
| SCHEMBL14430095 | 0.85 | CCR2 (0.47) | CCR2 | |
| SCHEMBL5333449 | 0.85 | CCR2 (0.47) | CCR2 | |
| SCHEMBL5326189 | 0.82 | CCR2 (0.55) | CCR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197590-A1 | SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS | JANSSEN PHARMACEUTCA N.V. (BE) | 2007-08-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197590-A1 | SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS | CCR2, CCR1, CCR5 | CCR2 1/4885TDP1 3488/4885KDM4E 3992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.